Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer

Celcuity (NASDAQ: CELC) said the FDA granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer. The approval shifts the company to a commercial-stage business, which should materially improve its near-term outlook versus prior developmental-phase expectations.

Analysis

Celcuity (NASDAQ: CELC) said the FDA granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer. The approval shifts the company to a commercial-stage business, which should materially improve its near-term outlook versus prior developmental-phase expectations.